SAB Biotherapeutics (SABS) Receivables - Accured (2024 - 2026)
SAB Biotherapeutics' (SABS) quarterly Receivables - Accured came in at $1.6 million in Q1 2026, up 7381.53% YoY from $21386.0 in Q1 2025, and up 68.99% on a QoQ basis from $946781.0 in Q4 2025.
SAB Biotherapeutics (SABS) Receivables - Accured (2024 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 3 years of Receivables - Accured data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Receivables - Accured rose 7381.53% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 7381.53% YoY) and the FY2025 annual result came in at $946781.0, up 1622.83% from the prior year.
- Receivables - Accured improved to $1.6 million in Q1 2026, from $946781.0 in the prior quarter.
- In the past five years, Receivables - Accured ranged from a high of $1.6 million in Q1 2026 to a low of $21386.0 in Q1 2025.
- A 3-year average of $462294.4 and a median of $209116.0 in 2024 frame the typical range for Receivables - Accured.
- Annual changes were most pronounced in 2025 — Receivables - Accured tumbled 88.93% — and 2026, when it surged 7381.53%.
- Tracing SABS's Receivables - Accured over 3 years: stood at $54955.0 in 2024, then soared by 1622.83% to $946781.0 in 2025, then surged by 68.99% to $1.6 million in 2026.
- The last three Receivables - Accured figures came in at $1.6 million (Q1 2026), $946781.0 (Q4 2025), and $559954.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.84 Mn |
| Jun 30, 2026 | 1.84 Mn |
| Mar 31, 2026 | 1.60 Mn |
| Mar 31, 2026 | 1.60 Mn |
| Dec 31, 2025 | 946,781.00 |
| Dec 31, 2025 | 946,781.00 |
| Sep 30, 2025 | 559,954.00 |
| Sep 30, 2025 | 559,954.00 |
| Mar 31, 2025 | 21,386.00 |
| Mar 31, 2025 | 21,386.00 |
| Dec 31, 2024 | 54,955.00 |
| Dec 31, 2024 | 54,955.00 |
| Sep 30, 2024 | 97,047.00 |
| Sep 30, 2024 | 97,047.00 |
| Jun 30, 2024 | 225,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Mar 31, 2024 | 193,232.00 |
| Mar 31, 2024 | 193,232.00 |